Literature DB >> 881699

Survival in polymyositis: corticosteroids and risk factors.

J R Carpenter, T W Bunch, A G Engel, P C O'Brien.   

Abstract

Thirty-one polymyositis patients treated with low-dose corticosteroid were age and sex matched with 31 polymyositis patients treated with high-dose corticosteroid. Although disease severity at onset of the study was similar in the groups, no statistically significant difference in survival was found. The death rate in each group was greater than normal. The presence of dysphagia or severe muscle weakness lessened the chances of survival. Controlled trials with other drugs should be carried out.

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 881699

Source DB:  PubMed          Journal:  J Rheumatol        ISSN： 0315-162X            Impact factor:   4.666


  14 in total

1.  Prognosis and mortality of polymyositis and dermatomyositis patients.

Authors:  A Airio; H Kautiainen; M Hakala
Journal:  Clin Rheumatol       Date:  2006-02-14       Impact factor: 2.980

Review 2.  Treatment of inflammatory myopathies.

Authors:  A C Cordeiro; D A Isenberg
Journal:  Postgrad Med J       Date:  2006-07       Impact factor: 2.401

Review 3.  Recognition and management of myositis.

Authors:  P Cherin
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

Review 4.  Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis.

Authors:  Patrick A Gordon; John B Winer; Jessica E Hoogendijk; Ernest H S Choy
Journal:  Cochrane Database Syst Rev       Date:  2012-08-15

Review 5.  Morbidity and mortality in adult polymyositis and dermatomyositis.

Authors:  Isabelle Marie
Journal:  Curr Rheumatol Rep       Date:  2012-06       Impact factor: 4.592

6.  Cyclosporine A as treatment of esophageal involvement in dermatomyositis.

Authors:  Sumiyuki Mii; Shiro Niiyama; Mai Kusunoki; Satoru Arai; Kensei Katsuoka
Journal:  Rheumatol Int       Date:  2006-08-10       Impact factor: 2.631

7.  Long-term outcome in polymyositis and dermatomyositis.

Authors:  I M Bronner; M F G van der Meulen; M de Visser; S Kalmijn; W J van Venrooij; A E Voskuyl; H J Dinant; W H J P Linssen; J H J Wokke; J E Hoogendijk
Journal:  Ann Rheum Dis       Date:  2006-04-10       Impact factor: 19.103

8.  Development of autoantibodies against muscle-specific FHL1 in severe inflammatory myopathies.

Authors:  Inka Albrecht; Cecilia Wick; Åsa Hallgren; Anna Tjärnlund; Kanneboyina Nagaraju; Felipe Andrade; Kathryn Thompson; William Coley; Aditi Phadke; Lina-Marcela Diaz-Gallo; Matteo Bottai; Inger Nennesmo; Karine Chemin; Jessica Herrath; Karin Johansson; Anders Wikberg; A Jimmy Ytterberg; Roman A Zubarev; Olof Danielsson; Olga Krystufkova; Jiri Vencovsky; Nils Landegren; Marie Wahren-Herlenius; Leonid Padyukov; Olle Kämpe; Ingrid E Lundberg
Journal:  J Clin Invest       Date:  2015-11-09       Impact factor: 14.808

9.  Pancreatic adenocarcinoma-associated polymyositis treated with corticosteroids along with cancer specific treatment: case report.

Authors:  John Syrios; Georgios Kechagias; Ioannis D Xynos; Maria N Gamaletsou; Aristea Papageorgiou; George Agrogiannis; Nicolas Tsavaris
Journal:  BMC Gastroenterol       Date:  2011-04-07       Impact factor: 3.067

10.  Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine.

Authors:  Elena Schiopu; Kristine Phillips; Paul M MacDonald; Leslie J Crofford; Emily C Somers
Journal:  Arthritis Res Ther       Date:  2012-01-27       Impact factor: 5.156
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.